Parameta Logo
parameta logo
Indices and Derivatives

Macroeconomic Outlook

Ovie Koloko
By Ovie Koloko, Chief Product Officer Feb 15, 2024

Persistent inflation has been the scourge of central banks for two years. Ever since Russia invaded Ukraine and provoked a global energy crisis, monetary policy committees have been forced to drive up interest rates in a bid to bring spiralling prices under control.

That intervention has proved largely successful with inflation starting to ease, but rates remain frustratingly sticky which is keeping interest rates higher. In the US inflation is predicted to sit at 3.4% this year[1], the UK’s consumer prices index rate is forecast to average 3.1% in Q4 2024[2], and the European Central Bank forecasts rates of 2.7% by end of the year[3].

Projections for interest rates across these major western economies are for falls but only slowly and cuts are unlikely to come before the second half of the year. And while inflation is nowhere near the double-digits of 2022, if it refuses to continue a downward trajectory, we can expect central banks to revert to quantitative tightening measures. Further contributing to the macroeconomic uncertainty this year is the not insignificant factor of the election Supercycle which sees more than half the world head to the polls. This massive electoral activity includes both the UK and US, which will affect both domestic and global economies, creating a major source of near-term uncertainty. The recent period of quantitative tightening (QT) means central banks no longer dominate the demand for debt. Replacing them are investors who expect a greater reward for holding longer-dated bonds. As such 2024 will likely see a steeper yield curves, with a larger difference between long- and short-term bonds. This environment tips the balance away from traditional income-generating asset classes, such as equities, towards long-term bonds for potentially reliable sources of return. On the flipside, as QT starts to ease, investors may look to corporate issuers for better interest rates. This may well leave them vulnerable to risk of default, especially if the more pessimistic predictions of a hard landing in tough financial conditions are realised. For investors attempting to navigate this unpredictable landscape, particularly those with asset/liability profiles linked to inflation and interest rates, implementing swap strategies could provide greater comfort for the future.

Growth in the over the counter (OTC) derivatives market is testament to the importance of inflation and interest swaps in managing volatility. The global Triennial OTC Derivatives market size was valued at USD 18.38 million in 2024 and is expected to expand at a CAGR of 3.14% to 2031, reaching USD 22.11 million by 2027[4].

However, with so many more players operating in the OTC market, and with myriad factors influencing how the markets behave, investors need access to reliable data to help inform decision making and ensure best execution. Last year we launched a new family of interest rate swap volatility (IRSV) indices which provide market participants with a forward-looking implied volatility measure for some of the most liquid option expiry, swap tenor combinations in the EUR and GBP interest rate swap markets. The indices, which are informed by input data and analytics from ICAP, use a theoretical foundation for measuring interest rate swap volatility, providing market participants with a model-free measure of spot implied volatility. This approach has been shown to have superior predictive power over other commonly used volatility forecasting measures.[SG1] [5] Such data driven indices will continue to evolve to offer investors tools to better navigate and inform their interactions with the inflation swaps market, with Parameta Solutions offering some exciting developments in this space in 2024. The end may be in sight for high inflation but there is still a long way to go before desirable levels are met, and investors can expect some bumps this year before normal services are resumed. In the meantime, an evolving and advancing OTC derivative market supported by cutting edge data and analytics, will provide much needed assurance as the year plays out.

© 2024 ICAP Information Services Limited (“IISL”). This communication is provided by ICAP Information Services Limited or a member of its group (“Parameta”) and all information contained in or attached hereto (the “Information”) is for information purposes only and is confidential. Access to the Information by anyone other than the intended recipient is unauthorised without Parameta’s prior written approval. The Information may not be not used or disclosed for any purpose without Parameta’s prior written approval, including without limitation, storing, copying, distributing, licensing, selling or displaying the Information, using the Information in an application or to create derived data of any kind, co-mingling the Information with any other data or using the data for any unlawful purpose of for any purpose that would cause it to become a benchmark under any law, regulation or guidance.

The Information is not, and should not be construed as, a live price, an offer, bid, recommendation or solicitation in relation to any financial instrument or investment or to participate in any particular trading strategy or constituting financial or investment advice or a financial promotion. The Information is not to be relied upon for any purpose whatsoever and is provided “as is” without warranty of any kind, either expressly or by implication, including without limitation as to completeness, timeliness, accuracy, continuity, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed, to the fullest extent possible under applicable law. In no circumstances will Parameta be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. Parameta may suspend, withdraw or modify or change the terms of the provision of the Information at any time in its sole discretion, without notice.

All rights, including without limitation intellectual property rights, in and to the Information are, and shall remain, the property of IISL or its licensors. Use of, access to or delivery of Parameta’s products and/or services requires a prior written licence from Parameta or its relevant affiliates. The terms of this disclaimer are governed by the laws of England and Wales.

image
Request Follow Up

You are one step closer to unlocking the value of our data and solutions. Fill out the form so that we can connect you to the right person.

Speak to our team